181 related articles for article (PubMed ID: 36586472)
1. FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations.
Ackley D; Birkebak J; Blumel J; Bourcier T; de Zafra C; Goodwin A; Halpern W; Herzyk D; Kronenberg S; Mauthe R; Shenton J; Shuey D; Wange RL
Regul Toxicol Pharmacol; 2023 Feb; 138():105327. PubMed ID: 36586472
[TBL] [Abstract][Full Text] [Related]
2. Considerations regarding the use of nonhuman primates in assessing safety endpoints for pharmaceuticals.
Brown PC; Wange RL
Regul Toxicol Pharmacol; 2023 Sep; 143():105449. PubMed ID: 37453554
[TBL] [Abstract][Full Text] [Related]
3. Nonhuman primate models for evaluation of SARS-CoV-2 vaccines.
Neil JA; Griffith M; Godfrey DI; Purcell DFJ; Deliyannis G; Jackson D; Rockman S; Subbarao K; Nolan T
Expert Rev Vaccines; 2022 Aug; 21(8):1055-1070. PubMed ID: 35652289
[TBL] [Abstract][Full Text] [Related]
4. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
[TBL] [Abstract][Full Text] [Related]
5. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.
Ménochet K; Yu H; Wang B; Tibbitts J; Hsu CP; Kamath AV; Richter WF; Baumann A
MAbs; 2022; 14(1):2145997. PubMed ID: 36418217
[TBL] [Abstract][Full Text] [Related]
6. Non-Human Primate Husbandry and Impact on Non-Human Primates Health: Outcomes From an IQ DruSafe/3RS Industrial Benchmark Survey.
Salian-Mehta S; Poling J; Birkebak J; Rensing S; Carosino C; Santos R; West W; Adams K; Orsted K; Fillman-Holliday D; Burns M
Int J Toxicol; 2023; 42(2):111-121. PubMed ID: 36543758
[TBL] [Abstract][Full Text] [Related]
7. Overview of Nonhuman Primate Models of SARS-CoV-2 Infection.
Trichel AM
Comp Med; 2021 Oct; 71(5):411-432. PubMed ID: 34548126
[TBL] [Abstract][Full Text] [Related]
8. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
[TBL] [Abstract][Full Text] [Related]
9. An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017).
Adams K; Clemons D; Impelluso LC; Lee D; Maguire S; Myers A; Petursson C; Schulingkamp R; Trouba K; Wright M
Toxicol Pathol; 2019 Jul; 47(5):649-655. PubMed ID: 31280699
[TBL] [Abstract][Full Text] [Related]
10. A critical evaluation of developmental and reproductive toxicology in nonhuman primates.
Faqi AS
Syst Biol Reprod Med; 2012 Feb; 58(1):23-32. PubMed ID: 22239078
[TBL] [Abstract][Full Text] [Related]
11. Applying the 3Rs to neuroscience research involving nonhuman primates.
Lemon RN
Drug Discov Today; 2018 Sep; 23(9):1574-1577. PubMed ID: 29733893
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
[TBL] [Abstract][Full Text] [Related]
13. Nonhuman primates as models for the discovery and development of radiation countermeasures.
Singh VK; Olabisi AO
Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
[TBL] [Abstract][Full Text] [Related]
14. Eliminating Potential Effects of Other Infections During Selection of Nonhuman Primates for COVID-19 Research.
Andrade MCR; Lemos BRP; Silva LM; Pecotte JK
Comp Med; 2023 Feb; 73(1):45-57. PubMed ID: 36744555
[TBL] [Abstract][Full Text] [Related]
15. Selected Resources for Pathology Evaluation of Nonhuman Primates in Nonclinical Safety Assessment.
Bolon B; Everitt JI
Toxicol Pathol; 2022 Jul; 50(5):725-732. PubMed ID: 35481786
[TBL] [Abstract][Full Text] [Related]
16. Experimental primates and non-human primate (NHP) models of human diseases in China: current status and progress.
Zhang XL; Pang W; Hu XT; Li JL; Yao YG; Zheng YT
Dongwuxue Yanjiu; 2014 Nov; 35(6):447-64. PubMed ID: 25465081
[TBL] [Abstract][Full Text] [Related]
17. Animal Models of COVID-19: Nonhuman Primates.
Singh DK; Cole J; Escobedo RA; Alfson KJ; Singh B; Lee TH; Alvarez X; Ganatra SR; Carrion R; Kaushal D
Methods Mol Biol; 2022; 2452():227-258. PubMed ID: 35554911
[TBL] [Abstract][Full Text] [Related]
18. No Evidence of SARS-CoV-2 Infection in Neotropical Primates Sampled During COVID-19 Pandemic in Minas Gerais and Rio Grande do Sul, Brazil.
de Abreu FVS; Macedo MV; da Silva AJJ; de Oliveira CH; de Ottone VO; de Almeida MAB; Dos Santos E; da Cardoso JC; Campos AS; da Silva CMD; da Silva AG; de Andrade MS; Bernis VMO; Bernis Filho WO; de Trindade GS; Albuquerque GR; da Sevá AP; Ribeiro BM; Teixeira DS; Campos FS; Franco AC; Roehe PM; de Oliveira DB
Ecohealth; 2021 Dec; 18(4):414-420. PubMed ID: 34843021
[TBL] [Abstract][Full Text] [Related]
19. B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates.
Bai Y; He Q; Yang J; Lu S; Mao Q; Gao F; Bian L; Zhang J; An C; Liu J; Wu X; Yu W; Wang Z; Peng X; Wang J; Liang Z; Xu M
Microbiol Spectr; 2022 Oct; 10(5):e0226322. PubMed ID: 36069561
[TBL] [Abstract][Full Text] [Related]
20. Applying the 3Rs to non-human primate research: Barriers and solutions.
Prescott MJ; Langermans JA; Ragan I
Drug Discov Today Dis Models; 2017; 23():51-56. PubMed ID: 33777153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
